Copenhagen, Toulouse – June 20, 2024. AdaptVac, a Danish clinical-stage biotech company, is announcing a collaboration with GTP Bioways, a leading French CDMO, for the production of a GMP batch of a placental malaria vaccine (PAMVAC) that will be used for a phase 1 clinical trial. This innovative vaccine aims at reducing the number of doses needed and improving the longevity of the vaccine-induced immune response for placental malaria. To know more
